New drug combo aims to shrink breast tumors before surgery
NCT ID NCT06144944
First seen Oct 31, 2025 · Last updated May 01, 2026 · Updated 25 times
Summary
This study tests whether adding the targeted drug pyrotinib to standard chemotherapy can better shrink tumors before surgery in people with a common type of early breast cancer (HR-positive, HER2-low). About 160 adults with high-risk, early-stage disease will be randomly assigned to receive either the combination or chemotherapy alone. The main goal is to see how many patients have little or no cancer remaining after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY-STAGE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, 510120, China
Conditions
Explore the condition pages connected to this study.